American Society of Clinical Oncology (ASCO), 2021


  1. Outcomes With KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma in ZUMA-2 Who Had Progression of Disease Within 24 Months of Diagnosis (POD24)
  2. Phase 2 Results of the ZUMA 3 Study Evaluating KTE X19, an Anti CD19 Chimeric Antigen Receptor T Cell Therapy, in Adult Patients With Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
  3. Outcomes in ZUMA‑5 With Axicabtagene Ciloleucel (Axi‑Cel) in Patients With Relapsed / Refractory Indolent Non‑Hodgkin Lymphoma Who Had the High‑Risk Feature of Progression Within 24 Months From Initiation of First Anti‑CD20–Containing Chemoimmunotherapy (POD24)
  4. Favorable Tumor Immune Microenvironment and Robust CAR T‑Cell Expansion May Overcome Tumor Burden and Promote Durable Efficacy With Axicabtagene Ciloleucel in Large B‑Cell Lymphoma
  5. Updated Outcomes With Axicabtagene Ciloleucel (Axi-Cel) Retreatment in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma in ZUMA-5
  6. Real World Evidence of Axicabtagene Ciloleucel (Axi Cel) for the Treatment of Large B Cell Lymphoma in the United States